• ATM Inhibition Promotes Macropinocytosis and Metabolic Adapt

  2026-05-22

  This study reveals that ATM kinase inhibition stimulates macropinocytosis, enhancing cancer cell survival in nutrient-poor environments. The findings identify a novel metabolic vulnerability induced by ATM inhibition, offering new avenues for combination cancer therapies targeting both DNA damage response and nutrient scavenging pathways.

• TCF25 Regulates Lysosomal Adaptation and Cell Death in Gluco

  2026-05-22

  Ren et al. (2025) identify TCF25 as a critical nutrient sensor that orchestrates cellular adaptation and cell death during glucose starvation by enhancing lysosomal acidification and ferritinophagy. These findings reveal a novel regulatory axis with implications for metabolic and ischemic disease models.

• Sulfo-NHS-Biotin in Single-Cell Functional Screening: New Fr

  2026-05-21

  Explore the advanced role of Sulfo-NHS-Biotin in high-throughput single-cell screening and cell therapy innovation. This article delves into the reagent’s mechanism, scientific advances, and unique applications, offering insights not found in standard protein labeling guides.

• GSH and GSSG Assay Kit: Advancing Reduced Glutathione Detect

  2026-05-21

  The GSH and GSSG Assay Kit streamlines redox state analysis, enabling reliable quantification of reduced and oxidized glutathione in diverse biological samples. This comprehensive guide delivers actionable workflows, troubleshooting strategies, and translational insights for researchers studying oxidative stress, immunometabolism, and tumor biology.

• HERC5-Driven IRF3 ISGylation Promotes Podocyte Injury in Lup

  2026-05-20

  This study uncovers a novel mechanism by which HERC5-mediated ISGylation of IRF3 stabilizes the transcription factor, leading to sustained IFN-β production and inflammatory injury in podocytes central to lupus nephritis. The findings highlight HERC5 as a potential therapeutic target for mitigating glomerular damage in autoimmune kidney disease.

• GSH and GSSG Assay Kit: Precision Tools for Tumor Hypoxia an

  2026-05-20

  Explore advanced applications of the GSH and GSSG Assay Kit in reduced glutathione detection and tumor immunometabolism research. This article provides a deep dive into assay methodology, mechanistic insights, and novel guidance for redox state analysis beyond conventional approaches.

• AP20187 in Conditional Gene Therapy: Unveiling Dimerization

  2026-05-19

  Explore how AP20187, a chemical inducer of dimerization, enables precision-controlled gene therapy and fusion protein regulation. Discover new insights on pathway selectivity and experimental design, grounded in recent proteomics research.

• Gramine Induces Ferroptosis in TNBC via CUL3–MTDH Modulation

  2026-05-19

  The referenced study reveals that gramine, a natural indole alkaloid, selectively suppresses triple-negative breast cancer (TNBC) by inducing ferroptosis through the CUL3–MTDH ubiquitination pathway. This mechanistic insight suggests a promising direction for therapeutic intervention in aggressive breast cancer subtypes and highlights the value of targeted cell viability assays for mechanistic validation.

• Brefeldin A: Applied ER Stress and Apoptosis Induction in Ca

  2026-05-18

  Brefeldin A (BFA) enables precise, reproducible induction of ER stress and apoptosis in cancer cell models, leveraging its unique blockade of ER-to-Golgi trafficking. This article details practical workflows, troubleshooting strategies, and assay innovations that maximize BFA’s utility for mechanistic and translational research.

• Difloxacin HCl: Advancing Antimicrobial and MDR Reversal Ass

  2026-05-18

  Difloxacin HCl stands at the forefront of quinolone antimicrobial antibiotic research, uniquely bridging robust antimicrobial susceptibility workflows and cutting-edge multidrug resistance (MDR) reversal assays. This article delivers actionable protocols, troubleshooting expertise, and translational insights—empowering scientists to harness APExBIO's high-purity Difloxacin HCl for next-generation microbiology and oncology investigations.

• Phosphoproteomic Adaptation to Chronic Cabozantinib in RCC

  2026-05-17

  This study demonstrates that chronic exposure to Cabozantinib (XL184) in renal cell carcinoma (RCC) leads to distinct, timescale-dependent remodeling of the phosphoproteome, particularly in adhesion- and motility-associated pathways. These findings clarify how RCC cells adapt under sustained multi-kinase inhibition, providing a systems-level framework for future research into resistance mechanisms and therapeutic strategies.

• GSK343 EZH2 Inhibitor: Precision Workflows in Epigenetic Can

  2026-05-16

  GSK343, a potent and selective EZH2 inhibitor, enables streamlined, reproducible inhibition of histone H3K27 trimethylation in in vitro cancer models. This guide details protocol enhancements, advanced troubleshooting, and practical workflow tips to maximize GSK343’s value in epigenetic cancer research.

• AG-221 (Enasidenib) in IDH2-Mutant AML: Applied Workflows &

  2026-05-15

  AG-221 (Enasidenib) empowers acute myeloid leukemia research by precisely inhibiting mutant IDH2, enabling robust oncometabolite quantification and differentiation assays. This guide translates advanced metabolic insights and peer-validated workflows into actionable protocols—ensuring reproducibility, troubleshooting clarity, and translational impact.

• Sulfaphenazole: Applied CYP2C9 Inhibitor Workflows & Insight

  2026-05-15

  Sulfaphenazole is a potent, selective CYP2C9 inhibitor with validated applications in vascular endothelial research, drug metabolism modulation, and advanced wound healing models. This guide translates bench findings—such as rapid perfusion restoration in ischemic injury—into actionable protocols and troubleshooting advice, empowering researchers to leverage Sulfaphenazole’s full experimental potential.

• RSL3 Glutathione Peroxidase 4 Inhibitor: Precision Ferroptos

  2026-05-14

  RSL3 is reshaping cancer biology with its potent, selective inhibition of GPX4, enabling robust ferroptosis induction—especially in RAS-driven and therapy-resistant malignancies. This guide details optimized workflows, advanced applications, and troubleshooting strategies for maximizing the impact of RSL3 in redox and ferroptosis research.

472 records 12/32 page Previous Next First page 上5页 1112131415 下5页 Last page